Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sionna Therapeutics Secures Exclusive Worldwide Rights To Develop And Commercialize AbbVie's CF Compounds ABBV-2222

Author: Benzinga Newsdesk | July 16, 2024 08:06am

ABBV-3067, And ABBV-2851; Phase 2 Studies Show Clinical Efficacy; Sionna's NBD1 Stabilizers Combined With These Compounds Demonstrate Potential For Superior Efficacy In CFHBE Assay; AbbVie To Receive Upfront Payment, Equity Investment, And Eligible For Milestones And Royalties

Posted In: ABBV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist